EGFR tyrosine kinase inhibitors (TKIs) have improved outcomes for patients with NSCLC.1, 2, 3 The third-generation EGFR TKI osimertinib was found to have survival benefits than first-generation agents gefitinib and erlotinib, and it is now a standard of care for metastatic NSCLC.4 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.